Tragara Pharmaceuticals, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Tragara Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Tragara Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Tragara Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Tragara Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc. - Key Therapeutics; Tragara Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Tragara Pharmaceuticals, Inc. - News; Tragara Pharmaceuticals, Inc. - Latest Updates; Tragara Pharmaceuticals, Inc. - Pipeline; Tragara Pharmaceuticals, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Tragara Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Tragara Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Tragara Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Tragara Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Tragara Pharmaceuticals, Inc. - Brief Tragara Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Tragara Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Tragara Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Tragara Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Tragara Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Tragara Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Tragara Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Tragara Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Tragara Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc. - Key Therapeutics; Tragara Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Tragara Pharmaceuticals, Inc. - News; Tragara Pharmaceuticals, Inc. - Latest Updates; Tragara Pharmaceuticals, Inc. - Pipeline; Tragara Pharmaceuticals, Inc. - Discontinued/Dormant Projects
Tragara Pharmaceuticals, Inc. Snapshot
Tragara Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Tragara Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Tragara Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Pipeline Products Glance
Tragara Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Drug Profiles
Capoxigem
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Gemcitabine + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Pemetrexed
Product Description
Mechanism of Action
R&D Progress
Kymena
Product Description
Mechanism of Action
R&D Progress
SB1317
Product Description
Mechanism of Action
R&D Progress
TGO3
Product Description
Mechanism of Action
R&D Progress
Tragara Pharmaceuticals, Inc. – Pipeline Analysis
Tragara Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Tragara Pharmaceuticals, Inc. – Pipeline Products By Target
Tragara Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Tragara Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Tragara Pharmaceuticals, Inc. – Recent Pipeline Updates
Tragara Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Capoxigem + Lapatinib + Capecitabine
Tragara Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Tragara Pharmaceuticals, Inc., Recent Developments
Tragara Pharmaceuticals, Inc.- Press Release
May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02
Apr 14, 2009: Apricoxib Phase I Study Results To Be Presented At AACR In Denver
Apr 14, 2009: Tragara To Present Apricoxib Phase I Study Results At American Association for Cancer Research
Financial Deals Landscape
Tragara Pharmaceuticals, Inc., Deals Summary
Tragara Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Tragara Pharma Secures $5 Million In Series B Financing
Tragara Pharma Secures $40 Million In Series A Financing
Licensing Agreements
S*BIO Enters Into Licensing Agreement With Tragara Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Tragara Pharmaceuticals, Inc., Key Information
Tragara Pharmaceuticals, Inc., Key Facts
Tragara Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Tragara Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Tragara Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Phase II, 2012
Tragara Pharmaceuticals, Inc. – Phase I, 2012
Tragara Pharmaceuticals, Inc. – Pre-Clinical, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Tragara Pharmaceuticals, Inc. - Pipeline By Target, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Tragara Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Tragara Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Tragara Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Tragara Pharmaceuticals, Inc., Deals Summary
Tragara Pharma Secures $5 Million In Series B Financing
Tragara Pharma Secures $40 Million In Series A Financing
S*BIO Enters Into Licensing Agreement With Tragara Pharma
LIST OF FIGURES
Tragara Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Tragara Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Tragara Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Tragara Pharmaceuticals, Inc. - Pipeline By Target, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Tragara Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012
Tragara Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Tragara Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Tragara Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Pipeline Products Glance
Tragara Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Drug Profiles
Capoxigem
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Gemcitabine + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Capoxigem + Pemetrexed
Product Description
Mechanism of Action
R&D Progress
Kymena
Product Description
Mechanism of Action
R&D Progress
SB1317
Product Description
Mechanism of Action
R&D Progress
TGO3
Product Description
Mechanism of Action
R&D Progress
Tragara Pharmaceuticals, Inc. – Pipeline Analysis
Tragara Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Tragara Pharmaceuticals, Inc. – Pipeline Products By Target
Tragara Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Tragara Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Tragara Pharmaceuticals, Inc. – Recent Pipeline Updates
Tragara Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Capoxigem + Lapatinib + Capecitabine
Tragara Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Tragara Pharmaceuticals, Inc., Recent Developments
Tragara Pharmaceuticals, Inc.- Press Release
May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02
Apr 14, 2009: Apricoxib Phase I Study Results To Be Presented At AACR In Denver
Apr 14, 2009: Tragara To Present Apricoxib Phase I Study Results At American Association for Cancer Research
Financial Deals Landscape
Tragara Pharmaceuticals, Inc., Deals Summary
Tragara Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Tragara Pharma Secures $5 Million In Series B Financing
Tragara Pharma Secures $40 Million In Series A Financing
Licensing Agreements
S*BIO Enters Into Licensing Agreement With Tragara Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Tragara Pharmaceuticals, Inc., Key Information
Tragara Pharmaceuticals, Inc., Key Facts
Tragara Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Tragara Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Tragara Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Phase II, 2012
Tragara Pharmaceuticals, Inc. – Phase I, 2012
Tragara Pharmaceuticals, Inc. – Pre-Clinical, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Tragara Pharmaceuticals, Inc. - Pipeline By Target, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Tragara Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Tragara Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Tragara Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Tragara Pharmaceuticals, Inc., Deals Summary
Tragara Pharma Secures $5 Million In Series B Financing
Tragara Pharma Secures $40 Million In Series A Financing
S*BIO Enters Into Licensing Agreement With Tragara Pharma
LIST OF FIGURES
Tragara Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Tragara Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Tragara Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Tragara Pharmaceuticals, Inc. - Pipeline By Target, 2012
Tragara Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Tragara Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012
